2-(5-甲醛-2,4-二甲基-1H-吡咯-3-基)乙酸 | 52513-48-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(5-甲醛-2,4-二甲基-1H-吡咯-3-基)乙酸
• 英文名称: 2-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)acetic acid
• 英文别名: 2,4-Dimethyl-3-(carboxymethyl)-5-formylpyrrol；(5-formyl-2,4-dimethyl-pyrrol-3-yl)-acetic acid；(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)-acetic acid
• CAS: 52513-48-1
• 化学式: C₉H₁₁NO₃
• mdl: MFCD10000699
• 分子量: 181.191
• InChiKey: WAFGISWUPUETKX-UHFFFAOYSA-N

物化性质

• 沸点：
  383.9±42.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(4-chlorophenyl)-3-(2-oxo-2,3-dihydro-1H-indol-6-yl)urea 、 2-(5-甲醛-2,4-二甲基-1H-吡咯-3-基)乙酸 在 四氢吡咯 作用下， 以 乙醇 为溶剂， 以60%的产率得到(Z)-5-{6-[3-(4-chlorophenyl)-ureido]-2-oxo-1,2-dihydroindol-3-ylidene-methyl}-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and structure–activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors

  摘要：

  A series of new ureidoindolin-2-one derivatives were synthesized and evaluated as inhibitors of receptor tyrosine kinases. Investigation of structure-activity relationships at positions 5, 6, and 7 of the oxindole skeleton led to the identification of 6-ureido-substituted 3-pyrrolemethylidene-2-oxindole derivatives that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families of receptor tyrosine kinases. Several derivatives showed potency against the PDGFR inhibiting both its enzymatic and cellular functions in the single-digit nanomolar range. Among them, compound 35 was a potent inhibitor against tyrosine kinases, including VEGFR and PDGFR families, as well as Aurora kinases. Inhibitor 36 (non-substituted on the pyrrole or phenyl ring) had a moderate pharmacokinetic profile and completely inhibited tumor growth initiated with the myeloid leukemia cell line, MV4-11, in a subcutaneous xenograft model in BALB/c nude mice. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.021
• 作为产物：
  描述：

  2,4-Dimethyl-3-carboxymethylpyrrol 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以96%的产率得到2-(5-甲醛-2,4-二甲基-1H-吡咯-3-基)乙酸
  参考文献：
  名称：

  Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)

  摘要：

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。

  公开号：

  US20040266843A1

文献信息

• Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
  申请人：Sugen, Inc.

  公开号：US20040266843A1

  公开（公告）日：2004-12-30

  The present invention relates generally to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). In particular, it relates to sulfonamide substituted indolinones which inhibit DNA-PK.

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。
• 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
  申请人：SUGEN, INC.

  公开号：US20030125370A1

  公开（公告）日：2003-07-03

  The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular met kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

  本发明涉及某些抑制激酶的5-烷基磺酰基-3-(吡咯-2-基甲烯基)-2-吲哚酮衍生物，特别是met激酶。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗激酶介导的疾病的方法，以及它们的制备方法。
• 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020187978A1

  公开（公告）日：2002-12-12

  The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

  本发明涉及某些4-杂环芳基-3-杂环芳基亚亚基-2-吲哚酮化合物及其生理上可接受的盐，这些化合物调节蛋白激酶（“PKs”）的活性，特别是CDK2。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020183319A1

  公开（公告）日：2002-12-05

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , X, Y, and Z are defined herein. The invention fuirther relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  该发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。本文披露的特定4-取代的7-氮杂吲哚-2-酮属于第11式和其药学上可接受的盐、溶剂合物、包合物和前药，其中R1、R2、R3、R4、X、Y和Z在此定义。该发明还涉及包含第1式化合物的药物组合物和剂型，以及其用于治疗和/或预防癌症等疾病的方法。
• [EN] 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS<br/>[FR] 7-AZA-INDOLINE-2-ONES SUBSTITUES EN 4 ET LEUR UTILISATION COMME INHIBITEURS DE PROTEINE KINASE
  申请人：SUGEN INC

  公开号：WO2001046196A1

  公开（公告）日：2001-06-28

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of formula (1) and pharmaceuitaclly acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of formula (1) and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  本发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。特别是，在此披露的4-取代的7-氮杂吲哚-2-酮的公式（1）及其药物可接受的盐，溶剂合物，包合物和前药，其中R1，R2，R3，R4，X，Y和Z在此定义。本发明还涉及包含公式（1）化合物的制药组合物和剂型，以及它们用于治疗和/或预防癌症等疾病的方法，但不限于此。